Protective effect of nasal immunization of influenza virus hemagglutinin with recombinant cholera toxin B subunit as a mucosal adjuvant in mice

Microbiology and Immunology

Volumn 52, Issue 2, 2008, Pages 55-63

  Isaka, Masanori ^a   Zhao, Yanqiu ^a,d   Nobusawa, Eri ^a   Nakajima, Setsuko ^a   Nakajima, Katsuhisa ^a   Yasuda, Yoko ^a,e   Matsui, Hideyuki ^a   Hasegawa, Tadao ^a   Maeyama, Jun Ichi ^b   Morokuma, Kazunori ^c   Ohkuma, Kunio ^c   Tochikubo, Kunio ^a  

^a NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^b NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^c Chemo Sero Therapeutic Research Institute   (Japan)

^d JILIN UNIVERSITY   (China)

^e KINJO GAKUIN UNIVERSITY   (Japan)

Author keywords

Hemagglutinin; Influenza; Mucosal adjuvant; rCTB

Indexed keywords

CHOLERA TOXIN B SUBUNIT; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G; IMMUNOLOGICAL ADJUVANT; INFLUENZA VACCINE; RECOMBINANT CHOLERA TOXIN B SUBUNIT; RECOMBINANT VACCINE; UNCLASSIFIED DRUG; VIRUS HEMAGGLUTININ; CHOLERA TOXIN; HEMAGGLUTININ HA1, INFLUENZA B VIRUS; HEMAGGLUTININ, HUMAN INFLUENZA A VIRUS; IMMUNOGLOBULIN A; INFLUENZA VIRUS HEMAGGLUTININ; VIRUS ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY BLOOD LEVEL; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; FEMALE; HUMORAL IMMUNITY; INFLUENZA; INFLUENZA VACCINATION; INFLUENZA VIRUS; INFLUENZA VIRUS A; INFLUENZA VIRUS B; MORBIDITY; MORTALITY; MOUSE; MUCOSAL IMMUNITY; NONHUMAN; PNEUMONIA; RESPIRATORY SYSTEM; SURVIVAL; VIRUS NEUTRALIZATION; ANIMAL; BAGG ALBINO MOUSE; BLOOD; HEMAGGLUTINATION INHIBITION TEST; IMMUNOLOGY; INTRANASAL DRUG ADMINISTRATION; LUNG; ORTHOMYXOVIRUS INFECTION; PATHOLOGY; SERODIAGNOSIS;

CERCOPITHECINE HERPESVIRUS 1; INFLUENZA A VIRUS; MUS; ORTHOMYXOVIRIDAE;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRANASAL; ANIMALS; ANTIBODIES, VIRAL; CHOLERA TOXIN; FEMALE; HEMAGGLUTINATION INHIBITION TESTS; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; IMMUNITY, MUCOSAL; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; INFLUENZA VACCINES; LUNG; MICE; MICE, INBRED BALB C; NEUTRALIZATION TESTS; ORTHOMYXOVIRIDAE INFECTIONS; RESPIRATORY SYSTEM; SURVIVAL ANALYSIS;

EID: 51449094833     PISSN: 03855600     EISSN: 13480421     Source Type: Journal    
DOI: 10.1111/j.1348-0421.2008.00010.x     Document Type: Article

References (34)

1. Clements J.D., Hartzog N.M., Lyon F.L. (1988) Adjuvant activity of Escherichia coli heat-labile enterotoxin and effect on the induction of oral tolerance in mice to unrelated protein antigens. Vaccine 6: 269-77.
2. DeHaan L., Feil I.K., VerweijW.R., et al. (1998) Mutational analysis of the role of ADP-ribosylation activity and GM1-binding activity in the adjuvant properties of the Escherichia coli heat-labile enterotoxin towards intranasally administered keyhole limpet hemocyanin. Eur J Immunol 28: 1243-50.
3. Elson C.O., EaldingW. (1984) Cholera toxin feeding did not induce oral tolerance in mice and abrogated oral tolerance to an unrelated protein antigen. J Immunol 133: 2892-2897.
4. Lycke N., Holmgren J. (1986) Strong adjuvant properties of cholera toxin on gut mucosal immune responses to orally presented antigens. Immunology 59: 301-8.
5. Tamura S., Samegai Y., Kurata H., et al. (1988) Protection against influenza virus infection by vaccine inoculated intranasally with cholera toxin B subunit. Vaccine 6: 409-13.
6. Lee A., Chen M. (1994) Successful immunization against gastric infection with Helicobacter species: use of a cholera toxin B-subunit-whole-cell vaccine. Infect Immun 62: 3594-97.
7. Oien N.L., Brideau R.J.,Walsh E.E.,WathenM.W. (1994) Induction of local and systemic immunity against human respiratory syncytial virus using a chimeric FG glycoprotein and cholera toxin B subunit. Vaccine 12(8): 731-5.
8. Yasuda Y., Matano K., Asai T., Tochikubo K. (1998) Affinity purification of recombinant cholera toxin B subunit oligomer expressed in Bacillus brevis for potential human use as a mucosal adjuvant. FEMS Immunol Med Microbiol 20(4): 311-8.
9. Isaka M., Yasuda Y., Mizokami M., et al. (2001) Mucosal immunization against hepatitis B virus by intranasal co-administration of recombinant hepatitis B surface antigen and recombinant cholera toxin B subunit as an adjuvant. Vaccine 19(11-12): 1460-6.
10. Goto N., Maeyama J., Yasuda Y., et al. (2000) Safety evaluation of recombinant cholera toxin B subunit produced by Bacillus brevis as a mucosal adjuvant. Vaccine 18(20): 2164-71.
11. Isaka M., Yasuda Y., Kozuka S., et al. (1998) Systemic and mucosal immune responses of mice to aluminium-adsorbed or aluminium-non-adsorbed tetanus toxoid administered intranasally with recombinant cholera toxin B. Vaccine 16(17): 1620-6.
12. Isaka M., Yasuda Y., Kozuka S., et al. (2000) Induction of systemic and mucosal antibody responses in mice immunized intranasally with aluminium- non-adsorbed diphtheria toxoid together with recombinant cholera toxin B subunit as an adjuvant. Vaccine 18(7-8): 743-51.
13. Isaka M., Komiya T., Takahashi M., et al. (2004) Recombinant cholera toxin subunit (rCTB) as a mucosal adjuvant enhances induction of diphtheria and tetanus antitoxin antibodies in mice by intranasal administration with diphtheria-pertussis-tetanus (DPT) combination vaccine. Vaccine 22: 3061-8.
14. Isaka M., Yasuda Y., Taniguchi T., et al. (2003) Mucosal and systemic antibody responses against an acellular pertussis vaccine in mice after intranasal co-administration with recombinant cholera toxin B subunit as an adjuvant. Vaccine 21(11-12): 1165-73.
15. Kubota E., Joh T., Tanida S., et al. (2005) Oral vaccination against Helicobacter pylori with recombinant cholera toxin B-subunit. Helicobacter 10(4): 345-352.
16. Yasuda Y., Isaka M., Taniguchi T., et al. (2003) Frequent nasal administrations of recombinant cholera toxin B subunit (rCTB)-containing tetanus and diphtheria toxoid vaccines induced antigen-specific serum and mucosal immune responses in the presence of anti-rCTB antibodies. Vaccine 21(21-22): 2954-63.
17. Maeyama J., Isaka M., Yasuda Y., et al. (2004) Effects of recombinant cholera toxin b subunit (rCTB) on cellular immune responses: enhancement of delayed-type hypersensitivity following intranasal co-administration of Mycobacterium bovis-BCG with rCTB. Microbiol Immunol 48(6): 457-63.
18. Maeyama J., Isaka M., Yasuda Y., et al. (2002) Effects of recombinant cholera toxin B subunit on IL-1beta production by macrophages in vitro. Microbiol Immunol 46: 593-9.
19. Isomura I., Yasuda Y., Tsujimura K., et al. (2005) Recombinant cholera toxin B subunit activates dendritic cells and enhances antitumor immunity. Microbiol Immunol 49(1): 79-87.
20. Ichikawa Y., Yamagata H., Tochikubo K., Udaka S. (1993) Very efficient extracellular production of cholera toxin B subunit using Bacillus brevis. FEMS Microbiol Lett 111(2-3): 219-24.
21. Visweswaraiah A., Novotny L.A., Hjemdahl-Monsen E.J., Bakaletz L.O., Thanavala Y. (2002) Tracking the tissue distribution of marker dye following intranasal delivery in mice and chinchillas: a multifactorial analysis of parameters affecting nasal retention. Vaccine 20(25-26): 3209-20.
22. Maeyama J., Isaka M., Yasuda Y., et al. (2001) Cytokine responses to recombinant cholera toxin B subunit produced by Bacillus brevis as a mucosal adjuvant. Microbiol Immunol 45(2): 111-7.
23. Tochikubo K., Isaka M., Yasuda Y., et al. (1998) Recombinant cholera toxin B subunit acts as an adjuvant for the mucosal and systemic responses of mice to mucosally co-administered bovine serum albumin. Vaccine 16(2-3): 150-5.
24. Murphy B.R., Clements M.L. (1989) The systemic and mucosal immune response of humans to influenza A virus. Curr Top Microb Immunol 146: 107-16.
25. Mbawuike I.N., Pacheco S., Acuna C.L., Switzer K.C., Zhang Y., Harriman G.R. (1999)Mucosal immunity to influenza without IgA: an IgA knockout mouse model. J Immunol 162: 2530-7.
26. De Haan L., VerweijW.R., Holtrop M., et al. (2001) Nasal or intramuscular immunization of mice with influenza subunit antigen and the B subunit of Escherichia coli heat-labile toxin induces IgA- or IgG-mediated protective mucosal immunity. Vaccine 19: 2898-907.
27. Watanabe I., Hagiwara Y., Kadowaki S., et al. (2002) Characterization of protective immune responses induced by nasal influenza vaccine containing mutant cholera toxin as a safe adjuvant (CT112K). Vaccine 20: 3443-55.
28. Baba T.W., Liska V., Hofmann-Lehmann R., et al. (2000) Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection. Nat Med 6: 200-6.
29. Mascola J.R., Stiegler G., VanCott T.C., et al. (2000) Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat Med 6: 207-10.
30. Tamura S., Yamanaka A., Shimohara M., et al. (1994) Synergistic action of cholera toxin B subunit (and Escherichia coli heat-labile toxin B subunit) and a trace amount of cholera whole toxin as an adjuvant for nasal influenza vaccine. Vaccine 12(5): 419-26.
31. Tamura S., Asanuma H., Tomita T., et al. (1994) Escherichia coli heat-labile enterotoxin B subunits supplemented with a trace amount of the holotoxin as an adjuvant for nasal influenza vaccine. Vaccine 12(12): 1083-9.
32. Reed L.J., Muench H. (1938) A simple method of estimating fifty per cent endpoints. Am J Hyg 27: 493-7.
33. Robinson H.L., Boyle C.A., Feltquate D.M., Morin M.J., Santoro J.C.,Webster R.G. (1997) DNA immunization for influenza virus: studies using hemagglutinin- and nucleoprotein-expressing DNAs. J Infect Dis 176(Suppl 1): S50-5.
34. VerweijW.R., DeHaan L., Holtrop M., et al. (1998) Mucosal immunoadjuvant activity of recombinant Escherichia coli heat-labile entertoxin and its B subunit: Induction of systemic IgG and secretory IgA responses in mice by intranasal immunization with influenza virus surface antigen. Vaccine 16(20): 2069-76.